Jim Cramer recommends buying hated stock Eli Lilly, while also praising Coinbase and IES Holdings. Marvell and Apple are also solid bets.

Imagine a world where doctors could give their patients a list of every clinical trial they are eligible to join.

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Growth stocks have soared this year as investors bet on an improving economic environment and technology players involved in ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

FLRG focuses on large- and mid-cap US companies, emphasizing valuation and quality, among others. Read why FLRG ETF is a ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Alexandria Real Estate Equities (ARE), a company credited with developing several science campuses in San Diego, recently ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), retaining the price target of $970.00. Don't Miss our Black Friday Offers: David Risinger ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...